A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)

(2011) D. J. Kuhn et al.   CURRENT CANCER DRUG TARGETS

Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress

(2010) Ulrike Seifert et al.   CELL

Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry

(2010) E. Genin et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis

(2010) N. Schmidt et al.   GUT

Thymoproteasome Shapes Immunocompetent Repertoire of CD8+ T Cells

(2010) Takeshi Nitta et al.   IMMUNITY

Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome

(2010) M. Basler et al.   JOURNAL OF IMMUNOLOGY

Bortezomib Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to TRAIL-Mediated Apoptosis via Activation of Both Extrinsic and Intrinsic Apoptosis Pathways

(2010) N. Seki et al.   MOLECULAR CANCER THERAPEUTICS

Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules

(2010) B. Guillaume et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy

(2009) Han-Ming Shen et al.   APOPTOSIS

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

The Biological Functions of NF-κB1 (p ) and its Potential as an Anti-Cancer Target

(2009) Yonghui Yu et al.   CURRENT CANCER DRUG TARGETS

No Splicing, No Dicing: Non-proteolytic Roles of the Ubiquitin-Proteasome System in Transcription

(2009) Thomas Kodadek   JOURNAL OF BIOLOGICAL CHEMISTRY

Obovatol Enhances Docetaxel-Induced Prostate and Colon Cancer Cell Death Through Inactivation of Nuclear Transcription Factor-κB

(2009) So Yong Lee et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

(2009) Tony Muchamuel et al.   NATURE MEDICINE

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

(2008) Deborah J. Kuhn et al.   BLOOD

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

(2008) A. A. Argyriou et al.   BLOOD

The role of the NFκB signalling pathway in cancer

(2008) María Cortés Sempere et al.   Clinical & Translational Oncology

Bortezomib-Mediated Inhibition of Steroid Receptor Coactivator-3 Degradation Leads to Activated Akt

(2008) G. Ayala et al.   CLINICAL CANCER RESEARCH

Proteasome modulators: essential chemical genetic tools for understanding human diseases

(2008) Marie Wehenkel et al.   Molecular BioSystems